Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease.

[1]  H. Razavi,et al.  Nonalcoholic fatty liver disease burden: Australia, 2019–2030 , 2020, Journal of gastroenterology and hepatology.

[2]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[3]  Z. Goodman,et al.  The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials , 2019, Hepatology.

[4]  Monica A. Tincopa,et al.  Incidence and Risks for Non Alcoholic Fatty Liver Disease and Steatohepatitis Post Liver Transplant: Systematic Review and Meta-analysis. , 2019, Transplantation.

[5]  N. Sattar,et al.  Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults , 2019, BMJ.

[6]  O. Cummings,et al.  Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease , 2019, JAMA network open.

[7]  A. Suzuki,et al.  Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps , 2019, Hepatology.

[8]  E. Tsochatzis,et al.  Management of metabolic syndrome and cardiovascular risk after liver transplantation. , 2019, The lancet. Gastroenterology & hepatology.

[9]  Kathleen F. Kerr,et al.  Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. , 2019, Journal of hepatology.

[10]  P. Angus,et al.  Handgrip Strength Adds More Prognostic Value to the Model for End‐Stage Liver Disease Score Than Imaging‐Based Measures of Muscle Mass in Men With Cirrhosis , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  L. Longworth,et al.  Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[12]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[13]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[14]  W. Rosenberg,et al.  Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease , 2019, BMC Gastroenterology.

[15]  M. Anvari,et al.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  M. Ekstedt,et al.  Collagen proportionate area is an independent predictor of long‐term outcome in patients with non‐alcoholic fatty liver disease , 2019, Alimentary pharmacology & therapeutics.

[17]  Z. Younossi.  Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[18]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  P. Angus,et al.  Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  E. Tsochatzis,et al.  International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. , 2019, Transplantation.

[21]  A. Allen,et al.  Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation , 2019, Transplantation.

[22]  J. Roberts,et al.  Should Patients With NAFLD/NASH Be Surveyed for HCC? , 2019, Transplantation.

[23]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[24]  S. Asch,et al.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[25]  Sunita Ghosh,et al.  Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. , 2018, Journal of hepatology.

[26]  J. Heimbach,et al.  Long‐term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy , 2018, Hepatology.

[27]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[28]  E. Benjamin,et al.  A simple clinical model predicts incident hepatic steatosis in a community‐based cohort: The Framingham Heart Study , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[29]  R. Bhogal,et al.  Ex situ machine perfusion as a tool to recondition steatotic donor livers: Troublesome features of fatty livers and the role of defatting therapies. A systematic review. , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  E. Tsochatzis,et al.  Non-alcoholic fatty liver disease and the interface between primary and secondary care. , 2018, The lancet. Gastroenterology & hepatology.

[31]  S. Hohmann,et al.  Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation , 2018, Transplantation.

[32]  Shelly C. Lu,et al.  NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances , 2018, The American Journal of Gastroenterology.

[33]  L. Adams,et al.  Burden of non‐alcoholic fatty liver disease in Australia , 2018, Journal of gastroenterology and hepatology.

[34]  M. Haberal,et al.  Liver Biopsy Results in Potential Donor Evaluation in Living Related Liver Transplant. , 2018, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[35]  P. Marcellin,et al.  Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[36]  T. Card,et al.  Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross‐sectional study using transient elastography , 2018, Alimentary pharmacology & therapeutics.

[37]  M. Eslam,et al.  Genetics and epigenetics of NAFLD and NASH: Clinical impact. , 2018, Journal of hepatology.

[38]  E. Bugianesi,et al.  Should we undertake surveillance for HCC in patients with NAFLD? , 2018, Journal of hepatology.

[39]  D. Schuppan,et al.  Determinants of fibrosis progression and regression in NASH. , 2018, Journal of hepatology.

[40]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[41]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[42]  Shari S. Rogal,et al.  Liver Transplantation in the Obese Cirrhotic Patient , 2017, Transplantation.

[43]  P. Puri,et al.  Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes , 2017, Digestive Diseases and Sciences.

[44]  T. Card,et al.  Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study , 2017, BMJ Open.

[45]  A. Barritt,et al.  NAFLD and liver transplantation: Current burden and expected challenges. , 2016, Journal of hepatology.

[46]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[47]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[48]  E. Tsochatzis,et al.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.

[49]  S. Francque,et al.  Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. , 2016, Journal of hepatology.

[50]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[51]  Q. Anstee,et al.  Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.

[52]  L. Henry,et al.  Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. , 2016, Gastroenterology.

[53]  F. Piscaglia,et al.  Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study , 2016, Hepatology.

[54]  R. Wiesner,et al.  Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States , 2016, Transplantation.

[55]  L. Henry,et al.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 , 2015, Hepatology.

[56]  S. Biggins,et al.  Low, rather than high, body mass index confers increased risk for post‐liver transplant death and graft loss: Risk modulated by model for end‐stage liver disease , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[57]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[58]  M. Sawyer,et al.  Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis , 2015, Journal of cachexia, sarcopenia and muscle.

[59]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[60]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[61]  A. Dare,et al.  Donor Hepatic Steatosis and Outcome After Liver Transplantation: a Systematic Review , 2015, Journal of Gastrointestinal Surgery.

[62]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[64]  Aijaz Ahmed,et al.  Diabetes Mellitus, and Not Obesity, Is Associated with Lower Survival Following Liver Transplantation , 2015, Digestive Diseases and Sciences.

[65]  Ming‐Lung Yu,et al.  Association between response to pegylated interferon/ribavirin therapy and ribavirin levels , 2015, Hepatology.

[66]  S. Saab,et al.  Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta‐analysis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[67]  S. Saab,et al.  The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US , 2014, Alimentary pharmacology & therapeutics.

[68]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.

[69]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[70]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[71]  A. Barritt,et al.  Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[72]  P. Galle,et al.  Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[73]  J. Neuberger,et al.  Long‐term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[74]  J. Feinglass,et al.  Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events , 2012, Hepatology.

[75]  V. Baracos,et al.  Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[76]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[77]  G. Ioannou,et al.  Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[78]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[79]  Vincent Wai-Sun Wong,et al.  Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography , 2011, Gut.

[80]  G. Avey,et al.  NAFLD Recurrence in Liver Transplant Recipients , 2011, Transplantation.

[81]  K. Watt,et al.  Metabolic syndrome and liver transplantation: a review and guide to management. , 2010, Journal of hepatology.

[82]  G. Klintmalm,et al.  Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[83]  S. Nair,et al.  Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: A single‐center study , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[84]  V. Paradis,et al.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis , 2009, Hepatology.

[85]  P. Thuluvath,et al.  Steroid avoidance in liver transplantation: Meta‐analysis and meta‐regression of randomized trials , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[86]  M. Malinchoc,et al.  The Impact of Obesity on Long‐term Outcomes in Liver Transplant Recipients—Results of the NIDDK Liver Transplant Database , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[87]  N. Sattar,et al.  Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo‐controlled trial , 2006, Clinical endocrinology.

[88]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[89]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[90]  J. Neuberger,et al.  Weight gain and obesity after liver transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[91]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[92]  S. Knechtle,et al.  The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. , 1991, Transplantation.

[93]  M. Laryea,et al.  Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. , 2019, Transplantation.

[94]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[95]  A. Burroughs,et al.  EASL Clinical Practice Guidelines: Liver transplantation. , 2016, Journal of hepatology.

[96]  M. Cole,et al.  Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. , 2014, Journal of hepatology.